---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123369"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:28:09.312436+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M

## Summary
- Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).
- Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.
- clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.
- MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.
- Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M.

## SEC filing metadata
- accession: 0000950170-24-123369
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/0000950170-24-123369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/adpt-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123369
- JSON: https://secwatch.observer/filing/0000950170-24-123369.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.